21:14 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Solid tumors Cell culture and mouse studies suggest combining Votrient pazopanib and a potassium channel inhibitor could help treat rhabdoid tumors. High throughput screening of a library of approved drugs in six human rhabdoid...
07:00 , May 13, 2013 |  BioCentury  |  Product Development

An association for dissociation

Forest Laboratories Inc.'s investment and option deal with Trevena Inc. last week will support the translation of a successful mechanism for treating chronic heart failure into the acute setting, as well as the development of...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Company News

Blue Ash Therapeutics, Forest Laboratories deal

Blue Ash granted Forest exclusive, worldwide rights to antiarrhythmic candidate azimilide. Last year, Blue Ash licensed the potassium channel blocker from Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland), which acquired the product in...
07:00 , Apr 25, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) gained $0.88 (22%) to $4.86 on Monday after clarifying the regulatory path in the U.S. for Northera droxidopa to treat neurogenic orthostatic hypotension (NOH). Chelsea still plans to submit...
01:10 , Apr 20, 2011 |  BC Extra  |  Company News

Azimilide finds its way to Forest

Blue Ash Therapeutics LLC (Cincinnati, Ohio) granted Forest Laboratories Inc. (NYSE:FRX) exclusive, worldwide rights to antiarrhythmic candidate azimilide. Last year, Blue Ash licensed the potassium channel blocker from Warner Chilcott plc (NASDAQ:WCRX), which acquired the...
08:00 , Nov 19, 2001 |  BC Week In Review  |  Clinical News

Azimilide: Phase III

In a placebo-controlled international Phase III study in 3,717 post-MI patients with a low left ventricular ejection fraction, azimilide had no adverse effect on all-cause mortality or survival. Patients at high risk of sudden death...